Wikipedia -WSS

Wikipedia

author：knowledge 2025-10-01 22:48:39 - browse：128

Adam's take main illustration — Molly Ferguson/STAT

The eye disease physician in charge of a committee that flagged a rare but severe side effect involving a newly approved drug from Apellis Pharmaceuticals has financial ties to a competing drugmaker. The conflict raises questions about his supervision of an emerging safety issue for patients and its impact on the financial health of Apellis.

Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic, failed to report consulting fees and stock ownership in Iveric Bio on a financial disclosure form maintained by the American Society of Retina Specialists, or ASRS. Iveric Bio is developing a treatment for geographic atrophy, a common, age-related cause of vision loss and the same indication for which the Apellis drug was approved.

The financial conflict, which was undisclosed until after Kaiser was contacted about it by STAT, is relevant because Kaiser also chairs a committee of the ASRS responsible for monitoring the safety of retina drugs and devices. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving injections of Syfovre, the treatment recently approved and launched by Apellis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Merck, Johnson & Johnson CEOs will testify on high drug prices

explore

WSS

Reconstructing family trees of blood cells may help predict disease

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Merck CEO won’t testify in Senate, citing no expertise in drug prices

New clues to why women have higher risk of autoimmune disorders

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Pancreatic cancer early detection could be helped by AI

hotspot

Wikipedia

Wikipedia

Anesthesiologist group: stop taking Ozempic before surgery

Pushing for an NIH office for post

In Memoriam: Notable people who died in 2023

Merck, Johnson & Johnson CEOs will testify on high drug prices

FDA approval of Sarepta Duchenne genetic therapy gives me hope

President Biden's budget: Here's what you might have missed

After affirmative action ruling, medical educators look to 'holistic review'

10 reasons why health care startups fail

Hepatitis C has a cure — but many Americans still lack access to it

Readout Newsletter: The latest on Novavax, Merck, Bluebird

hotspot

Humana’s losses in Medicare Advantage tank its stock

Why scientists need input from humanists on sensitive research

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Male and female sex labels in research insufficient, scientists say

John Green on his newest strategy for fighting tuberculosis

Bernie Sanders is gearing up to subpoena pharma CEOs

explore

explore

entertainment

Wikipedia